← Leaderboards
Leonidas A Stamatatos
Fred Hutchinson Cancer Center
$77,152,738
Attributed
$77,152,738
Total exposure
42
Grants
35
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $19.6M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$128,688,397 · 46
By mechanism
U19$71,321,221 · 20
P01$33,706,216 · 10
R01$20,885,573 · 5
R56$1,129,420 · 2
P51$920,217 · 7
R21$725,750 · 2
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Margaret Juliana McElrath$601,692,649
- Andrew McGuire$8,683,437
- Corey Casper$15,901,770
- Dan H. Barouch$218,203,090
- Lawrence Corey$859,232,520
Others in their field
Top investigators on “Neutralizing Antibody”
- Barton F Haynes · Duke University$361,488,167
- Dennis R. Burton · Scripps Research Institute$328,455,703
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,392,049
- Lawrence Corey · Fred Hutchinson Cancer Center$257,355,255
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$139,509,763
Research focus
Neutralizing AntibodyAntigensDesignAntibodiesImmunizationHiv-1B-LymphocytesInfectionVaccinesVirusMonitorProgramsBaseVaccinationGrantProductionResponseIn VivoEngineeringRecombinantsAntibody FormationReceptors, Antigen, B-CellEnv Gene ProductsEpitopes
Grant awards (167)
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs$1,415,922
U19 · FY2025 · AI · contact PI
Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization$873,050
R01 · FY2025 · AI · contact PI
Scientific Project One$525,472
U19 · FY2025 · AI · contact PI
Core-002$432,572
U19 · FY2025 · AI · contact PI
Project-002$215,682
U19 · FY2025 · AI · contact PI
ConProject-001$163,398
U19 · FY2025 · AI · contact PI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs$163,398
U19 · FY2025 · AI · contact PI
Admin-Core-001$137,792
U19 · FY2025 · AI · contact PI
Core-001$104,404
U19 · FY2025 · AI · contact PI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs$1,582,499
U19 · FY2024 · AI · contact PI
Project-002$1,393,751
U19 · FY2024 · AI · contact PI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs$1,393,751
U19 · FY2024 · AI · contact PI
Scientific Project One$800,602
U19 · FY2024 · AI · contact PI
Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization$349,040
R01 · FY2024 · AI · contact PI
Administrative Core$162,032
U19 · FY2024 · AI · contact PI
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs$2,099,783
U19 · FY2023 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$1,900,554
P01 · FY2023 · AI · contact PI
Scientific Project One$1,076,473
U19 · FY2023 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$638,291
P01 · FY2023 · AI · contact PI
Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization$589,260
R56 · FY2023 · AI · contact PI
Administrative Core$163,426
U19 · FY2023 · AI · contact PI
Administrative Core$64,198
P01 · FY2023 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$1,303,436
P01 · FY2022 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$586,646
P01 · FY2022 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$307,596
P01 · FY2022 · AI · contact PI
Administrative Core$204,283
P01 · FY2022 · AI · contact PI
Administrative Core$117,330
P01 · FY2022 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$117,329
P01 · FY2022 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$1,817,834
P01 · FY2021 · AI · contact PI
Defining BCR evolution during immunization$448,553
R01 · FY2021 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$410,413
P01 · FY2021 · AI · contact PI
Defining BCR evolution during immunization$172,916
R01 · FY2021 · AI · contact PI
Administrative Core$169,218
P01 · FY2021 · AI · contact PI
GMP Production of Envelope Immunogens$7,311,966
U19 · FY2020 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$4,886,015
U19 · FY2020 · AI · contact PI
Immunogen Design for Specific BCR Activation$1,997,824
U19 · FY2020 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$1,803,472
P01 · FY2020 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$645,753
R01 · FY2020 · AI · contact PI
Defining BCR evolution during immunization$621,477
R01 · FY2020 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$410,412
P01 · FY2020 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$202,713
U19 · FY2020 · AI · contact PI
Administrative Core$169,673
P01 · FY2020 · AI · contact PI
Administrative Core$138,897
U19 · FY2020 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$40,029
U19 · FY2020 · AI · contact PI
GMP Production of Envelope Immunogens$7,455,307
U19 · FY2019 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$5,005,133
U19 · FY2019 · AI · contact PI
Expansion and targeted maturation of germline HIV-1 bNAb-associated BCRs$1,790,906
P01 · FY2019 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$645,753
R01 · FY2019 · AI · contact PI
Defining BCR evolution during immunization$621,477
R01 · FY2019 · AI · contact PI
Development of prime-boost immunization schemes to elicit VRC01-class bNAbs in polyclonal human BCR backgrounds$406,892
P01 · FY2019 · AI · contact PI
Administrative Core$168,793
P01 · FY2019 · AI · contact PI
Administrative Core$125,768
U19 · FY2019 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$85,112
U19 · FY2019 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$53,953
U19 · FY2019 · AI · contact PI
Immunogen Design for Specific BCR Activation$19,252
U19 · FY2019 · AI · contact PI
GMP Production of Envelope Immunogens$2,163,028
U19 · FY2018 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$1,800,250
U19 · FY2018 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$723,506
U19 · FY2018 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$694,153
R01 · FY2018 · AI · contact PI
Defining BCR evolution during immunization$621,477
R01 · FY2018 · AI · contact PI
Immunogen Design for Specific BCR Activation$433,216
U19 · FY2018 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$420,049
U19 · FY2018 · AI · contact PI
Administrative Core$223,478
U19 · FY2018 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$1,821,474
U19 · FY2017 · AI · contact PI
GMP Production of Envelope Immunogens$1,317,107
U19 · FY2017 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$694,153
R01 · FY2017 · AI · contact PI
Defining BCR evolution during immunization$532,725
R01 · FY2017 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$225,049
U19 · FY2017 · AI · contact PI
Immunogen Design for Specific BCR Activation$134,568
U19 · FY2017 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$99,175
U19 · FY2017 · AI · contact PI
Administrative Core$45,575
U19 · FY2017 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$1,868,193
U19 · FY2016 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$1,038,590
U19 · FY2016 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$654,252
R01 · FY2016 · AI · contact PI
Defining BCR evolution during immunization$533,811
R01 · FY2016 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$361,185
U19 · FY2016 · AI · contact PI
Immunogen Design for Specific BCR Activation$311,106
U19 · FY2016 · AI · contact PI
Administrative Core$157,312
U19 · FY2016 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$7,732,619
U19 · FY2015 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$7,178,959
U19 · FY2015 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$2,046,594
P01 · FY2015 · AI · contact PI
Defining BCR evolution during immunization$740,759
R01 · FY2015 · AI · contact PI
Immunogen Production in Immunizations$512,339
P01 · FY2015 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$406,215
U19 · FY2015 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$384,647
P01 · FY2015 · AI · contact PI
Immunogen Design for Specific BCR Activation$275,179
U19 · FY2015 · AI · contact PI
Administrative Core$192,200
U19 · FY2015 · AI · contact PI
Administrative Core$121,501
P01 · FY2015 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$1,944,717
P01 · FY2014 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$1,066,201
U19 · FY2014 · AI · contact PI
Defining BCR evolution during immunization$909,731
R01 · FY2014 · AI · contact PI
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens$881,449
U19 · FY2014 · AI · contact PI
Preclinical Evaluation of Envelope Immunogens Optimized to Elicit VRCOI-class An$718,885
U19 · FY2014 · AI · contact PI
Immunogen Production in Immunizations$586,027
P01 · FY2014 · AI · contact PI
Immunogen Production in Immunizations$496,807
P01 · FY2014 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$483,570
P01 · FY2014 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$459,974
P01 · FY2014 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$384,532
P01 · FY2014 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$331,232
R01 · FY2014 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$310,698
P01 · FY2014 · AI · contact PI
Administrative Core$199,295
P01 · FY2014 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$162,682
R01 · FY2014 · AI · contact PI
Envelope Immunogen and Recombinant Antibody Production Core$157,399
U19 · FY2014 · AI · contact PI
Immunogen Design for Specific BCR Activation$146,535
U19 · FY2014 · AI · contact PI
Administrative Core$117,888
U19 · FY2014 · AI · contact PI
Administrative Core$88,671
P01 · FY2014 · AI · contact PI
Immunogen Design for Specific BCR Activation$77,415
U19 · FY2014 · AI · contact PI
Administrative Core$74,490
U19 · FY2014 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$2,124,372
P01 · FY2013 · AI · contact PI
Defining BCR evolution during immunization$650,449
R01 · FY2013 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$611,912
P01 · FY2013 · AI · contact PI
Immunogen Production in Immunizations$468,500
P01 · FY2013 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$458,229
R01 · FY2013 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$310,497
P01 · FY2013 · AI · contact PI
Immunogens and Formulation Core$239,525
P01 · FY2013 · AI · contact PI
Administrative Core$133,848
P01 · FY2013 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$2,180,408
P01 · FY2012 · AI · contact PI
Immunogen Production in Immunizations$642,380
P01 · FY2012 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$549,166
P01 · FY2012 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$540,160
R56 · FY2012 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$487,479
R01 · FY2012 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$463,646
P01 · FY2012 · AI · contact PI
Immunogens and Formulation Core$173,916
P01 · FY2012 · AI · contact PI
Administrative Core$173,234
P01 · FY2012 · AI · contact PI
Optimizing HIV immunogen-BCR interactions for vaccine development$1,935,501
P01 · FY2011 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$562,968
P01 · FY2011 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$487,675
R01 · FY2011 · AI · contact PI
Identifying B cell intracellular signaling networks that lead to b12 production$411,746
P01 · FY2011 · AI · contact PI
Immunogen Production in Immunizations$255,901
P01 · FY2011 · AI · contact PI
Immunogens and Formulation Core$218,973
P01 · FY2011 · AI · contact PI
Administrative Core$207,051
P01 · FY2011 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$574,184
P01 · FY2010 · AI · contact PI
Monitoring the development of anti-Env Abs during HIV infection$513,666
R01 · FY2010 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$276,067
R01 · FY2010 · AI · contact PI
Immunogens and Formulation Core$224,432
P01 · FY2010 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$750,287
R01 · FY2009 · AI · contact PI
Characterization of broad anti-HIV neutralizing antibody responses$586,972
P01 · FY2009 · AI · contact PI
Immunogens and Formulation Core$250,436
P01 · FY2009 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$631,882
R01 · FY2008 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$753,600
R01 · FY2007 · AI · contact PI
Protection from SHIV-infection by CTL and Antibodies$573,646
R01 · FY2006 · AI · contact PI
Vaccine Efficacy of Modified HIV Envelopes$500,240
R01 · FY2006 · AI · contact PI
PROTECTION FROM SHIV-INFECTION BY CTL AND ANTIBODIES$228,467
P51 · FY2006 · RR · contact PI
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$65,435
P51 · FY2006 · RR · contact PI
Protection from SHIV-infection by CTL and Antibodies$660,212
R01 · FY2005 · AI
Vaccine Efficacy of Modified HIV Envelopes$401,054
R01 · FY2005 · AI
PROTECTION FROM SHIV-INFECTION BY CTL AND ANTIBODIES$175,831
P51 · FY2005 · RR
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$52,511
P51 · FY2005 · RR
Protection from SHIV-infection by CTL and Antibodies$586,676
R01 · FY2004 · AI
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$409,352
R01 · FY2004 · AI
PROTECTION FROM SHIV-INFECTION BY CTL AND ANTIBODIES$161,398
P51 · FY2004 · RR
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$47,161
P51 · FY2004 · RR
Protection from SHIV-infection by CTL and Antibodies$596,358
R01 · FY2003 · AI
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$324,527
R01 · FY2003 · AI
Neutralizing MAbs elicited by modified HIV envelopes$268,500
R21 · FY2003 · AI
PROTECTION FROM SHIV-INFECTION BY CTL AND ANTIBODIES$189,414
P51 · FY2003 · RR
Protection from SHIV-infection by CTL and Antibodies$571,171
R01 · FY2002 · AI
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$379,009
R01 · FY2002 · AI
Neutralizing MAbs elicited by modified HIV envelopes$248,750
R21 · FY2002 · AI
ANTIBODY RESPONSES TO OLIGOMERIC HIV ENVELOPE FORMS: VACCINE$0
P51 · FY2002 · RR
NOVEL STRATEGY TO DELIVER ANTIGENS TO DENDRITIC CELLS: VACCINE &HIV$0
P51 · FY2002 · RR
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$364,171
R01 · FY2001 · AI
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$8,429
R01 · FY2001 · AI
ANTIBODY RESPONSES TO OLIGOMERIC HIV ENVELOPE FORMS: VACCINE$0
P51 · FY2001 · RR
NOVEL STRATEGY TO DELIVER ANTIGENS TO DENDRITIC CELLS: VACCINE &HIV$0
P51 · FY2001 · RR
VACCINE EFFICACY OF MODIFIED HIV ENVELOPES$248,400
R01 · FY2000 · AI
ANTIGENICITY OF HIV1 MODIFIED ENVELOPES$208,500
R21 · FY2000 · AI